Evidence map›Paper›PMID 41826719›Full record

ArticleMolecular neurobiology2026

The Interferon-miR-146a-5p-Stat1/Nrf2 Pathway Mediates LRRK2-R1441G-induced M1 over M2 Microglia Activation.

Lishan Lin, Junfeng Luo, Xiantao Wang, Tanvikhaa Saravanan, Gabriela Mercado, Yucheng Li, Ya Zhang, Liliana D Florea, Markus Hafner, Zhong Pei and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lishan LinDepartments of Psychiatry and Pharmacology, Division of Neurobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Junfeng LuoDepartment of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Xiantao WangRNA Molecular Biology Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Tanvikhaa SaravananDepartments of Psychiatry and Pharmacology, Division of Neurobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Gabriela MercadoDepartments of Psychiatry and Pharmacology, Division of Neurobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Yucheng LiDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Ya ZhangDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Liliana D FloreaDepartments of Genetic Medicine, Medicine and Computer Science, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Markus HafnerRNA Molecular Biology Laboratory, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Zhong PeiDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China. peizhong@mail.sysu.edu.cn.
Wanli W SmithDepartments of Psychiatry and Pharmacology, Division of Neurobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. wsmith60@jhmi.edu.

Funding

National Institute of Health RO1NS119208
6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease with movement disorder. The etiology and molecular pathogenesis of PD are not fully understood. Mutations in the LRRK2 gene are the primary genetic causes of PD and contribute to sporadic PD. Mitochondrial dysfunction and neuroinflammation have been reported in LRRK2-based PD models. However, the molecular mechanisms in LRRK2-linked PD remain largely unknown. In this study, we used a human microglial cell line (HMC-3) to study the effects of mutant LRRK2-R1441G and a mitochondrial toxin (MPP

Indexed as

InterferonsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MicrogliaMicroRNAsNF-E2-Related Factor 2Signal TransductionSTAT1 Transcription FactorCell LineHumansMutationInterferonsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanMicroRNAsNF-E2-Related Factor 2STAT1 protein, humanSTAT1 Transcription FactorLRRK2Microglia activationMiRNANeuroinflammationNrf2Stat1

Identifiers

PMID41826719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.